CD38 and lobular neoplasia: As shown in Figures 8B-G, results showed that there was no statistically significant difference in the effect of IBI379 on CD19/CD20 double-positive B cells compared to the control group (p > 0.05, Figure 8D), but IBI379 effectively kill CD19+CD20-CD38+ plasma cells in LN patients (p = 0.0328, Figure 8G).